Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Sees Significant Growth in Short Interest

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 6,680,000 shares, an increase of 12.5% from the December 15th total of 5,940,000 shares. Based on an average daily trading volume, of 975,100 shares, the short-interest ratio is currently 6.9 days.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX traded up $0.12 during trading hours on Friday, hitting $22.78. 4,930,123 shares of the company’s stock traded hands, compared to its average volume of 888,541. The stock’s fifty day moving average price is $21.75 and its two-hundred day moving average price is $20.20. The firm has a market cap of $2.72 billion, a P/E ratio of 19.31, a P/E/G ratio of 2.16 and a beta of 0.79. Catalyst Pharmaceuticals has a twelve month low of $13.12 and a twelve month high of $24.27.

Analyst Ratings Changes

Several analysts recently weighed in on the company. HC Wainwright boosted their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. Stephens assumed coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target on the stock. StockNews.com downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. Bank of America reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Finally, Truist Financial boosted their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $32.86.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock worth $1,754,140 in the last ninety days. Insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $50,000. Larson Financial Group LLC grew its stake in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 2,994 shares during the period. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $134,000. Finally, Quantbot Technologies LP bought a new stake in Catalyst Pharmaceuticals during the third quarter worth about $151,000. 79.22% of the stock is owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.